Morgan Stanley has initiated coverage on Agilent Technologies Inc (A) with an Overweight rating, marking the firm's first assessment of the company. This rating reflects Morgan Stanley's analysis of Agilent's business, industry dynamics, and growth prospects.
Agilent Technologies, headquartered in Santa Clara, California, operates in the Life Sciences Tools & Services sector and employs approximately 18,000 full-time staff. The company provides application-focused solutions for life sciences, diagnostics, and applied chemical markets. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment encompasses various activities, offering active pharmaceutical ingredients for oligo-based therapeutics, alongside a range of reagents, instruments, software, and consumables. The Agilent CrossLab segment delivers services and consumables across laboratories, while the Applied Markets segment focuses on instruments and software that help customers analyse physical and biological properties of substances.
As of December 1, 2025, Agilent's market capitalisation stands at $42.6 billion, with a price-to-earnings ratio (P/E) of 34.96 and an earnings per share (EPS) of 4.27. The company's dividend yield is reported at 68.0%. Upcoming earnings are anticipated on May 26, 2026, with an estimated EPS of $1.44 and revenue of $1.8 billion.
The announcement highlights the importance of analyst ratings, which provide insights based on research and financial modelling. However, such assessments are built on assumptions that may not always materialise. Investors are encouraged to consider a range of factors, including company fundamentals and industry trends, when making decisions. Analyst opinions can evolve with new information, and differing views may exist on the same company.
This update provides insight into the broader analyst consensus for Agilent, which currently includes 6 Strong Buy, 10 Buy, and 10 Hold ratings, reflecting a general sentiment of Buy among 26 analysts surveyed.